EUVIMEDEUVIMED entdecken
Crossref

CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies

Xinjian Yu, Pan Li, Heyuan Feng, Jian Kang, Yafeng Li, Shuangyou Liu iD

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqae166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Xinjian Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Flow Cytometry, Medical Laboratory, Beijing Gobroad Boren Hospital, Beijing, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, CD58 Antigens. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, there are no data available in relapsed/refractory (r/r) patients who have received long-term and multiline therapies, especially chimeric antigen receptor (CAR) T cells; here, we focused on investigating CD58 status in these patients.

Methods

CD58 expression on lymphoblasts was detected by multiparameter flow cytometry. CD58 status was evaluated in patients with r/r B-ALL before CAR-T therapy, and the patients who failed or relapsed after CAR-T.

Results

Among 274 pediatric and adult patients prior to exposure to CAR-T cells (22.3% of them underwent allogeneic hematopoietic cell transplantation, allo-HCT), 228 (83.2%) showed CD58 positivity. Furthermore, among 58 patients who were CD58 positive before CAR-T failed or relapsed after CAR-T (half also received CD22 CAR-T or allo-HCT as a consolidation treatment following CD19 CAR-T), the frequency of CD58 expression was 79.3% (46/58) in all patients and 86.2% (25/29) in patients exposed to CD19 CAR-T cells alone.

Conclusions

CD58 antigen was stably expressed in patients with r/r B-ALL after multiline therapies, including allo-HCT and CAR-T, indicating that it could still be a leukemic marker in heavily treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaCD58 AntigensHumansMaleChildFemaleAdultAdolescentChild, PreschoolYoung AdultMiddle AgedImmunotherapy, AdoptiveNeoplasm, ResidualInfantAgedRecurrenceNeoplasm Recurrence, LocalHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

CAR-T cell therapyCD58acute lymphoblastic leukemiaflow cytometryrelapsed/refractory

Substanzen

Biomarkers, TumorCD58 Antigens

Autor:innen und Institutionen

  • Division of Flow Cytometry, Medical Laboratory, Beijing Gobroad Boren Hospital, Beijing, China.
  • Department of Hematology, Beijing Gobroad Boren Hospital, Beijing, China.

ORCID-Profile: Shuangyou Liu

Zitieren

APA

Yu, X., Li, P., Feng, H., Kang, J., Li, Y., & Liu, S. (2025). CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae166

Vancouver

Yu X, Li P, Feng H, Kang J, Li Y, Liu S. CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae166

BibTeX
@article{Yu2025,
  author = {Yu, Xinjian and Li, Pan and Feng, Heyuan and Kang, Jian and Li, Yafeng and Liu, Shuangyou},
  title = {CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqae166}
}
Kostenlos starten →